Findings of ICER Final Evidence Report for multiple myeloma therapies
US health technology assessor the Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of three new treatments targeting the B-cell maturation antigen (BCMA) for heavily pre-treated patients with triple class refractory multiple myeloma (TCRMM) who have cycled through numerous previous lines of therapy:
- idecabtagene vicleucel (“ide-cel,” Abecma, from Bristol-Myers Squibb ([YSE BMY) and bluebird bio [Nasdaq: BLUE]), a chimeric antigen receptor (CAR) T-cell therapy that the Food and Drug Administration] approved in March 2021 to treat TCRMM patients after four or more prior lines of therapy;
- ciltacabtagene autoleucel (“cilta-cel,” from Johnson & Johnson [NYSE: JNJ} Janssen unit and Legend Biotech [Nasdaq: LEGN]), an investigational CAR T-cell therapy for which a rolling biologic license application (BLA) seeking approval for the treatment of adults with relapsed and refractory multiple myeloma was completed in the first quarter of 2021;
- belantamab mafodotin-blmf (“belantamab,” Blenrep, from GlaxoSmithKline [LSE: GSK), which the FDA approved in August 2020 to treat TCRMM patients after four or more prior lines of therapy.
Downloads: Final Evidence Report | Report-at-a-Glance | Policy Recommendations
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze